Daniela Rodrigues de Oliveira, Heber Victor Tolomeu, Carlos Alberto Manssour Fraga, Lídia Moreira Lima
{"title":"Rho kinase inhibitors: a patent review (2017-2023).","authors":"Daniela Rodrigues de Oliveira, Heber Victor Tolomeu, Carlos Alberto Manssour Fraga, Lídia Moreira Lima","doi":"10.1080/13543776.2025.2522735","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Rho-associated protein kinases (ROCK) play a crucial role in various biological processes, making them a valuable therapeutic target. Recent FDA approvals of ROCK-targeting drugs have brought renewed focus to this area, which this review aims to explore.</p><p><strong>Areas covered: </strong>This review examines patents published from 2017 to 2023, highlighting novel ROCK inhibitors, progress on previously studied compounds, and new therapeutic applications. A thorough literature search was conducted using patent databases and relevant publications.</p><p><strong>Expert opinion: </strong>Fasudil, ripasudil, netarsudil, and belumosudil are the primary ROCK inhibitors approved for human use. Despite some pharmacokinetic challenges, research in this field continues to advance, with significant potential for further clinical development.</p>","PeriodicalId":12314,"journal":{"name":"Expert Opinion on Therapeutic Patents","volume":" ","pages":"811-837"},"PeriodicalIF":4.6000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Opinion on Therapeutic Patents","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/13543776.2025.2522735","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/24 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Rho-associated protein kinases (ROCK) play a crucial role in various biological processes, making them a valuable therapeutic target. Recent FDA approvals of ROCK-targeting drugs have brought renewed focus to this area, which this review aims to explore.
Areas covered: This review examines patents published from 2017 to 2023, highlighting novel ROCK inhibitors, progress on previously studied compounds, and new therapeutic applications. A thorough literature search was conducted using patent databases and relevant publications.
Expert opinion: Fasudil, ripasudil, netarsudil, and belumosudil are the primary ROCK inhibitors approved for human use. Despite some pharmacokinetic challenges, research in this field continues to advance, with significant potential for further clinical development.
期刊介绍：
Expert Opinion on Therapeutic Patents (ISSN 1354-3776 [print], 1744-7674 [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles on recent pharmaceutical patent claims, providing expert opinion the scope for future development, in the context of the scientific literature.
The Editors welcome:
Reviews covering recent patent claims on compounds or applications with therapeutic potential, including biotherapeutics and small-molecule agents with specific molecular targets; and patenting trends in a particular therapeutic area
Patent Evaluations examining the aims and chemical and biological claims of individual patents
Perspectives on issues relating to intellectual property
The audience consists of scientists, managers and decision-makers in the pharmaceutical industry and others closely involved in R&D
Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
